Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16442)	11/18/2003 7:00:48 PM
From: Cacaito	Respond to of 17367

BiiB is very good merger, plenty of sales, cash, research, pipeline.plants, clinical and regulatory infrastructure and savings. $35 to $55 in 12 months. Antegren is a good play either way, BUT for less risk BiiB for more risk and more rewards Elan. I have plenty of money in both, but my future money is going to Elan, the Az program is almost a sure shot and it will be huge in the next 3 to 5 years, both clinically and for the share price.